SYN Key Stats
- Notable 52-Week Highs and Lows of the Day 12/12: (GNVC) (CYTR) (CORT) High; (IMUC) (SYN) (IAG) Low Street Insider Dec 12
- Unusual 11 Mid-Day Movers 12/12: (GNVC) (NLP) (ZN) Higher; (IMUC) (SPPR) (SYN) Lower Street Insider Dec 12
- Pre-Open Stock Movers 12/12: (BAXS) (UNS) (ARCW) Higher; (IMUC) (LULU) (CIEN) Lower (more...) Street Insider Dec 12
- Synthetic Biologics (SYN) Sinks After Pricing 11.5M Share Offering at $1 Street Insider Dec 12
- After Hours Stock Movers 12/11: (UNS) (PRTA) (FB) Higher; (IMUC) (ATHN) (SUNE) Lower (more...) Street Insider Dec 11
- Synthetic Biologics (SYN) Announces Common Stock Offering Street Insider Dec 11
- Synthetic Biologics to Present at the LD MICRO VI: Main Event Conference in Los Angeles noodls Dec 2
- Synthetic Biologics Management Discusses Q3 2013 Results - Earnings Call Transcript Seeking Alpha Nov 14
- Synthetic Biologics' SYN-004 for the Prevention of C. difficile Infections Named a "Top Project to Watch" by Elsevier Business Intelligence noodls Nov 14
- Synthetic Biologics Reports Third Quarter 2013 Financial Results and Operational Update noodls Nov 14
SYN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Synthetic Biologics is down 31.88% over the last year vs S&P 500 Total Return up 27.09%, Intrexon Corp up N/A, and ZIOPHARM Oncology down 12.73%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for SYN
Pro Strategies Featuring SYN
Did Synthetic Biologics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Synthetic Biologics Inc. is a biotechnology company engaged in the development of biologics for the prevention and treatment of serious infectious diseases.